In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated. Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology . 105(4) e213907. doi: 10.1212/WNL.0000000000213907
